GLP-1 Drugs Coverage Debate Among Employers

Nearly eight in 10 employers report that GLP-1s are driving an increase in their company's health care costs, leaving many to consider some difficult choices in balancing costs and care.

Objective Facts

According to a Business Group on Health survey completed in February-March 2026 by 105 employer members, nearly eight in 10 employers report that GLP-1s are driving an increase in their company's health care costs. While most employers cover GLP-1s for diabetes, 67% of surveyed employers currently cover GLP-1s for weight management. Of those covering GLP-1s for weight management, only 72% said they were likely to continue that coverage in 2027, while 10% said they likely would not. Employers rely on strategies such as validating clinical eligibility via objective biometric data, requiring participation in a weight management program, limiting prescribing to specific providers and excluding certain medications from the formulary. 87% of employers anticipate that the availability of an oral GLP-1 medication will result in higher demand for the drugs overall, and only 9% of employers anticipate a decrease in price.

Left-Leaning Perspective

Progressive and health equity-focused outlets have highlighted the access and equity dimensions of employer GLP-1 coverage decisions. The Johns Hopkins Bloomberg School of Public Health convened a panel on "GLP-1s and Employers: Taking a Health Equity Lens," noting that "while there is significant clinical promise and indications continue to accumulate, the costs of these treatments present coverage challenges to insurers and employers, who are increasingly limiting access and providing barriers to patients, and these barriers may interact with racial disparities present for many of these conditions." Katey Bey, Global Head of Total Rewards at Sedgwick, acknowledged the tension: "We want to ensure high quality of life for our participants, that's our number one goal, but then we also have the fiscal responsibility of controlling costs." However, health policy experts on the progressive side emphasize that "the individuals who might benefit most from their use may have the hardest time accessing them" due to steep prices. Left-leaning health advocates and the American Medical Association argue that treating obesity now saves the system billions in future costs related to heart disease and kidney failure. Employee Benefit News published an opinion by advocates noting "Many workers worry that GLP-1 coverage signals privilege, creating a two-tier system where only higher-paid employees or those on premium plans benefit" and that "without a broader well-being framework, these initiatives risk deepening divides between employees who qualify for medications and those who don't." Progressive policy experts also point to state-level momentum, with North Dakota recently becoming the first state to require certain insurance coverage for GLP-1 medications by adding them to its essential health benefits benchmark plan. Progressive coverage largely omits or downplays the concerns about utilization rates exceeding projections and questions about long-term ROI. While health equity advocates acknowledge cost pressures, they frame coverage restrictions primarily as a distributional justice problem requiring government intervention rather than as an inevitable market outcome.

Right-Leaning Perspective

Conservative, employer-focused, and market-oriented sources frame the employer GLP-1 coverage debate primarily through the lens of fiscal sustainability and cost containment. Ellen Kelsay of the Business Group on Health, representing major employers, stated the core concern: "Our findings show the tremendous concern employers have regarding these medications from a cost and financial viability perspective," and that "companies cannot ignore the reality that GLP-1s have significant implications for health care budgets." NPR's reporting on this issue quoted Chris Whaley, a benefits analyst, on the problem of employer "magical thinking": "Every study that's looked at that has shown that's absolutely not the case" that better health translates to lower costs, as "there's among employers, this kind of magic ideal that we can improve patient health and that's just going to be this magic wand that cuts employer health care spending." Right-leaning and market-oriented commentators emphasize the practical realities that only 1 in 12 members remain on GLP-1 treatment after three years, making long-term ROI projections speculative. UnitedHealthcare's Chief Data & Analytics Officer Craig Kurtzweil urged caution, arguing that employers should "consider a whole-person approach" rather than rush to GLP-1 coverage decisions, noting that "individuals who take these drugs are more successful at achieving and maintaining their weight loss goals when they are part of a comprehensive lifestyle management program, and employers get more value out of covering them when this is the case." Conservative policy voices support market-based solutions, including the Trump administration's TrumpRx platform offering "negotiated, lower-cost GLP-1 pricing directly to consumers," which has "prompted pharmaceutical companies to reconsider the price of the drugs and health plans to reevaluate coverage and cost containment strategies." Right-leaning coverage emphasizes employer flexibility and choice rather than mandates, focusing on how targeted access strategies and direct-to-consumer subsidies may be more fiscally prudent than broad benefit coverage. This perspective downplays equity concerns and frames coverage restrictions as reasonable cost management rather than access barriers.

Deep Dive

The GLP-1 employer coverage debate reflects a fundamental tension between clinical evidence and budgetary reality. National GLP-1 spending rose by more than 500% between 2018 and 2023, from $13.7 billion to $71.7 billion, and drugs are estimated to account for 14% of all prescription drug spending in 2026. Prescription drug costs are increasing around 13%-15% annually—and GLP-1 costs are fueling much of this growth, with total GLP-1 spend increasing around 50% in 2025 due to heightened utilization. This explosive growth has caught employers off-guard; many employers reported that utilization was higher than expected and covering them significantly increased prescription drug cost. Both perspectives contain legitimate concerns. Left-leaning advocates are correct that obesity contributes to more than 60 chronic conditions and results in 66% higher annual health care costs for affected individuals, costing the U.S. economy up to $1.72 trillion each year, and that sustained GLP-1 use shows measurable long-term cost reductions: diabetes patients saw medical costs drop 6%–9% after 30 months, and those using the drug for weight loss had 3%–7% lower costs within 18 months. However, the right is also correct that only 1 in 12 members remain on treatment after three years, meaning most employees never reach the point where long-term savings materialize. Additionally, 35% of consumers who reported using GLP-1 drugs said they had stopped taking the medications, and specifically 40% stopped because of affordability. This suggests that even when coverage is available, cost-sharing can undermine the adherence necessary to achieve projected savings. The equity dimension adds complexity. KFF estimates that 34% of non-elderly individuals with employer-sponsored insurance have a BMI that would medically qualify them for a GLP-1, but only 67% of surveyed employers currently cover GLP-1s for weight management. More concerning, half of 2,000 consumers surveyed by the Employee Benefit Research Institute did not know whether their employer covered GLP-1s, and of those who said such coverage was available, only four in 10 definitively had access for both diabetes and obesity. This suggests significant confusion and unequal access. Additionally, 27% of employees feel grateful about employer GLP-1 coverage, but 23% are concerned and 47% feel neutral, with workers worrying that GLP-1 coverage signals privilege and creates two-tier systems. What to watch: Several dynamics will reshape this debate. First, 87% of employers anticipate that the availability of an oral GLP-1 medication will result in higher demand for the drugs overall, and only 9% of employers anticipate a decrease in price, suggesting cost pressures will intensify. Second, although the BALANCE model is proceeding in Medicaid, hesitation to participate among Part D insurers led the model to be postponed indefinitely in Medicare, meaning government price negotiation strategies are facing resistance. Third, some states are moving toward coverage mandates, with North Dakota recently becoming the first state to require certain insurance coverage for GLP-1 medications by adding them to its essential health benefits benchmark plan, which could reshape employer obligations. Finally, of employers currently covering GLP-1s for weight management, only 72% said they were likely to continue that coverage in 2027, while 10% said they likely would not, indicating potential coverage reductions ahead that will heighten equity concerns.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

GLP-1 Drugs Coverage Debate Among Employers

Nearly eight in 10 employers report that GLP-1s are driving an increase in their company's health care costs, leaving many to consider some difficult choices in balancing costs and care.

May 19, 2026
What's Going On

According to a Business Group on Health survey completed in February-March 2026 by 105 employer members, nearly eight in 10 employers report that GLP-1s are driving an increase in their company's health care costs. While most employers cover GLP-1s for diabetes, 67% of surveyed employers currently cover GLP-1s for weight management. Of those covering GLP-1s for weight management, only 72% said they were likely to continue that coverage in 2027, while 10% said they likely would not. Employers rely on strategies such as validating clinical eligibility via objective biometric data, requiring participation in a weight management program, limiting prescribing to specific providers and excluding certain medications from the formulary. 87% of employers anticipate that the availability of an oral GLP-1 medication will result in higher demand for the drugs overall, and only 9% of employers anticipate a decrease in price.

Left says: Health equity advocates worry that high prices inhibit access and note that "there's been a disservice to real people who have obesity that now may not have easy access because of the associated knee jerk reactions of overemphasizing restriction." While clinical promise is significant, the costs of these treatments present coverage challenges to employers, who are increasingly limiting access and providing barriers that may interact with racial disparities present for these conditions.
Right says: Ellen Kelsay, president and CEO of Business Group on Health, stated: "Our findings show the tremendous concern employers have regarding these medications from a cost and financial viability perspective. Against the backdrop of anticipated double-digit health care cost increases, fueled to a large degree by GLP-1s and overall prescription drug costs, companies cannot ignore the reality that GLP-1s have significant implications for health care budgets." Conservative sources emphasize that "every study that's looked at that has shown that's absolutely not the case" that better health automatically translates into lower costs, and that employers have "a kind of magic ideal that we can improve patient health and that's just going to be this magic wand that cuts employer health care spending."
✓ Common Ground
Some voices on the left and right acknowledge that GLP-1 drugs show genuine clinical efficacy for weight loss and chronic disease management, though they disagree on how this should inform coverage decisions.
A number of commentators across the spectrum recognize that the GLP-1 market is still evolving, with new formulations, indications, and pricing models likely to shift in coming years, making one-time coverage decisions risky.
Diverse perspectives from employers, clinicians, and pharmaceutical manufacturers recognize that coverage barriers may disproportionately affect certain populations, and that health equity considerations deserve serious attention even within cost containment discussions.
Several analysts on both sides acknowledge that purely binary choices—either open-ended coverage or complete exclusion—are unsustainable, and that some form of structured access with clinical criteria and support programs may be most viable.
There appears to be emerging consensus that transparency from PBMs on rebates and cost structures is needed to make informed coverage decisions, though disagreement remains on what coverage levels are appropriate.
Objective Deep Dive

The GLP-1 employer coverage debate reflects a fundamental tension between clinical evidence and budgetary reality. National GLP-1 spending rose by more than 500% between 2018 and 2023, from $13.7 billion to $71.7 billion, and drugs are estimated to account for 14% of all prescription drug spending in 2026. Prescription drug costs are increasing around 13%-15% annually—and GLP-1 costs are fueling much of this growth, with total GLP-1 spend increasing around 50% in 2025 due to heightened utilization. This explosive growth has caught employers off-guard; many employers reported that utilization was higher than expected and covering them significantly increased prescription drug cost.

Both perspectives contain legitimate concerns. Left-leaning advocates are correct that obesity contributes to more than 60 chronic conditions and results in 66% higher annual health care costs for affected individuals, costing the U.S. economy up to $1.72 trillion each year, and that sustained GLP-1 use shows measurable long-term cost reductions: diabetes patients saw medical costs drop 6%–9% after 30 months, and those using the drug for weight loss had 3%–7% lower costs within 18 months. However, the right is also correct that only 1 in 12 members remain on treatment after three years, meaning most employees never reach the point where long-term savings materialize. Additionally, 35% of consumers who reported using GLP-1 drugs said they had stopped taking the medications, and specifically 40% stopped because of affordability. This suggests that even when coverage is available, cost-sharing can undermine the adherence necessary to achieve projected savings.

The equity dimension adds complexity. KFF estimates that 34% of non-elderly individuals with employer-sponsored insurance have a BMI that would medically qualify them for a GLP-1, but only 67% of surveyed employers currently cover GLP-1s for weight management. More concerning, half of 2,000 consumers surveyed by the Employee Benefit Research Institute did not know whether their employer covered GLP-1s, and of those who said such coverage was available, only four in 10 definitively had access for both diabetes and obesity. This suggests significant confusion and unequal access. Additionally, 27% of employees feel grateful about employer GLP-1 coverage, but 23% are concerned and 47% feel neutral, with workers worrying that GLP-1 coverage signals privilege and creates two-tier systems.

What to watch: Several dynamics will reshape this debate. First, 87% of employers anticipate that the availability of an oral GLP-1 medication will result in higher demand for the drugs overall, and only 9% of employers anticipate a decrease in price, suggesting cost pressures will intensify. Second, although the BALANCE model is proceeding in Medicaid, hesitation to participate among Part D insurers led the model to be postponed indefinitely in Medicare, meaning government price negotiation strategies are facing resistance. Third, some states are moving toward coverage mandates, with North Dakota recently becoming the first state to require certain insurance coverage for GLP-1 medications by adding them to its essential health benefits benchmark plan, which could reshape employer obligations. Finally, of employers currently covering GLP-1s for weight management, only 72% said they were likely to continue that coverage in 2027, while 10% said they likely would not, indicating potential coverage reductions ahead that will heighten equity concerns.

◈ Tone Comparison

Progressive sources use equity-focused language emphasizing "barriers," "disparities," and "fair access," while conservative/employer sources emphasize "fiscal responsibility," "cost pressures," and "difficult choices." Left-leaning voices often cite health outcomes and clinical benefits first, then note cost challenges; right-leaning voices lead with budget impact and sustainability concerns, positioning clinical benefits as secondary to financial viability.